278. Huge lymphatic malformation with cervicofacial lesion Clinical trials / Disease details

Clinical trials : 22 / Drugs : 27 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 63

11 trials found

diseases per page:

Showing 1 to 10 of 11 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04921722 (ClinicalTrials.gov)	October 22, 2021	6/6/2021	Percutaneous Administration of Sirolimusin the Treatment of Superficial Complicated Vascular Anomali ...	Percutaneous Administration of Sirolimusin the Treatment of Superficial Complicated Vascular Anomali ...	Kaposiform Hemangioendothelioma;Tufted Angioma;Superficial Vascular Anomalies;Superficial Lymphatic ...	Drug: Percutaneous sirolimus;Drug: Oral sirolimus	Children's Hospital of Fudan University	NULL	Recruiting	N/A	18 Years	All	75	Phase 4	China
2	NCT05050149 (ClinicalTrials.gov)	September 15, 2021	8/9/2021	Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcyst ...	A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus3.9% Topical ...	Microcystic Lymphatic Malformation	Drug: PTX-022	Palvella Therapeutics, Inc.	NULL	Recruiting	13 Years	N/A	All	15	Phase 2	United States
3	NCT04861064 (ClinicalTrials.gov)	May 18, 2021	23/4/2021	Weekly Sirolimus Therapy	Weekly Sirolimus Therapy for the Treatment of Venous and Lymphatic Malformations	Venous Malformation;Lymphatic Malformation	Drug: Sirolimus	Medical University of South Carolina	NULL	Recruiting	2 Years	N/A	All	24	Phase 2	United States
4	NCT04128722 (ClinicalTrials.gov)	February 14, 2020	24/9/2019	TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN	TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN	Lingual Microcystic Lymphatic Malformations	Drug: Sirolimus Oral Liquid Product 1mg/mL	University Hospital, Tours	NULL	Recruiting	5 Years	N/A	All	12	Phase 2	France
5	JPRN-UMIN000038973	2020/01/06	25/12/2019	A multicenter, phase 3 study assessing efficacy and safety of the Sirolimus(Granules and Tablets) in ...	A multicenter, phase 3 study assessing efficacy and safety of the Sirolimus(Granules and Tablets) in ...	Kaposiform hemangioendothelioma or Tufted angiomaLymphangioma (cystic lymphatic malformation), lymph ...	An initial dose of sirolimusis single orally administered under fed or fasting condition. Subsequent ...	Gifu University Hospital	NULL	Complete: follow-up continuing	1months-old	Not applicable	Male and Female	10	Phase 3	Japan
6	EUCTR2019-001530-33-FR (EUCTR)	29/06/2019	01/04/2019	TOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUN	TOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUN - TOPGUN	Lingual microcystic lymphatic malformations (LMLM) in children and adults MedDRA version: 20.0;Level ...	Trade Name: RAPAMUNE Product Name: Sirolimus 1mg/mL Product Code: L04AA10	CHRU TOURS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France
7	NCT03972592 (ClinicalTrials.gov)	June 5, 2019	24/5/2019	Topical Sirolimus in Cutaneous Lymphatic Malformations	0.1% Topical Sirolimusin the Treatment of Cutaneous Microcystic Lymphatic Malformations in Children ...	Vascular Malformations;Lymphatic Malformation	Drug: Topical 0.1% Sirolimus;Drug: Topical Vehicle	University Hospital, Tours	University Hospital, Angers	Recruiting	6 Years	N/A	All	55	Phase 2	France
8	EUCTR2018-001359-11-FR (EUCTR)	22/02/2019	23/07/2018	0.1% topical sirolimusin the treatment of cutaneous microcystic lymphatic malformations in children ...	0.1% topical sirolimusin the treatment of cutaneous microcystic lymphatic malformations in children ...	Cutaneous microcystic lymphatic malformations (CMLM) in children and adults MedDRA version: 20.0;Lev ...	Product Name: Sirolimus 0,1% crème INN or Proposed INN: SIROLIMUS	CHRU TOURS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	55	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France
9	NCT03243019 (ClinicalTrials.gov)	June 25, 2018	1/8/2017	Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations	Evaluation of the Efficacy of Rapamycinin the Treatment of Cervico-facial Lymphatic Malformations of ...	Lymphatic Malformation;Pediatric	Drug: rapamycin;Device: MRI;Biological: Rapamycin dosage	University Hospital, Lille	Ministry of Health, France	Recruiting	1 Year	18 Years	All	28	Phase 2	France
10	JPRN-UMIN000030522	2017/11/14	22/12/2017	A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimusin the Tr ...		Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lympha ...	Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus(2mg/day) is single orally administere ...	Gifu University	NULL	Recruiting	Not applicable	Not applicable	Male and Female	50	Not selected	Japan

First Previous1 2Next Last